Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy
Abstract
A total of 10%–20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 16, 2019
- Source ID
- 10.1093/jnci/djz075
Entities
People
- Alison Dunning
- Ana M. Carballo
- Ana Vega
- Andrea Baran
- Antonio Di Narzo
- Antonio Gómez-caamaño
- Barry S. Rosenstein
- Catharine M. West
- David P. Dearnaley
- Derick R. Peterson
- Emma Hall
- Gaurav Pandey
- Gillian C. Barnett
- Harry Ostrer
- Hiroshi Tsuji
- Ke Hao
- Kim Deruyck
- Laura Fachal
- Leila Dorling
- Matthew Parliament
- Matthew R Sydes
- Mehmet Eren Ahsen
- Michelle Hollenberg
- Michelle Janelsins
- Miguel E Aguado-Barrera
- Nawaid Usmani
- Neil G. Burnet
- Nelson N. Stone
- Paul D P Pharoah
- Paula Peleteiro
- Ramón Lobato-Busto
- Rebecca M Elliott
- Richard Stock
- Rosalind Eeles
- Sandeep Singhal
- Sarah Kerns
- Sarah L. Gulliford
- Shiro Saito
- Søren M Bentzen
- Takashi Imai
Organizations
- Albert Einstein College of Medicine
- Cancer Research UK
- Columbia University
- Ghent University Hospital
- Icahn School of Medicine at Mount Sinai
- Institute of Cancer Research
- National Institutes of Health
- The Royal Marsden NHS Foundation Trust
- United States Department of Defense
- University College London
- University of Alberta
- University of Cambridge
- University of Manchester
- University of Maryland
- University of Rochester
- University of Santiago de Compostela